Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions

被引：0

作者：

Liptrott, Neill J. ^{[1
]}

Giardiello, Marco ^{[2
]}

Hunter, Joseph W. ^{[2
]}

Tatham, Lee ^{[1
]}

Tidbury, Louise R. ^{[1
]}

Siccardi, Marco ^{[1
]}

Rannard, Steve ^{[2
]}

Owen, Andrew ^{[1
]}

机构：

[1] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool L69 3BX, Merseyside, England

[2] Univ Liverpool, Dept Chem, Liverpool L69 3BX, Merseyside, England

来源：

NANOMEDICINE | 2015年 / 10卷 / 09期

基金：

英国工程与自然科学研究理事会;

关键词：

nanoparticle; nanoparticle biological fate; protein corona; solid drug nanoparticle; CORONA; SIZE; TRANSFERRIN; DELIVERY; ALBUMIN; IMPACT; VITRO;

D O I：

10.2217/NNM.14.77

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Aim: Oral and intramuscular sustained-release antiretroviral solid drug nanoparticles (SDNs) are in development but there is limited understanding of whether nanoparticles or dissolved drug predominate systemically. Materials & methods: A flow cytometric method was developed to analyze SDNs in biological fluids such as plasma, including the putative formation of a protein corona. Results: SDNs were found to be stable in plasma and could be observed using the techniques developed here. In addition, transferrin, fibrinogen and albumin were found to be associated with SDNs upon incubation. Conclusion: This methodology has enabled us to determine protein interactions of SDNs in solution without the requirement of separation from the matrix. This will enable further studies of their biological fate.

引用

页码：1407 / 1421

页数：15

共 50 条

[1] APPLICATION OF GRADIENT FLOW-INJECTION ANALYSIS TO STUDIES OF DRUG - PROTEIN-BINDING
ABDULLAHI, GL
MILLER, JN
ANALYST, 1985, 110 (10) : 1271 - 1272
[2] PROTEIN-BINDING AND DRUG CLEARANCE
ROWLAND, M
CLINICAL PHARMACOKINETICS, 1984, 9 : 10 - 17
[3] PROTEIN-BINDING AND DRUG INTERACTIONS
SUDLOW, G
BIRKETT, DJ
WADE, DN
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1973, 3 (03): : 336 - 337
[4] DISEASES AND DRUG PROTEIN-BINDING
TILLEMENT, JP
LHOSTE, F
GIUDICELLI, JF
CLINICAL PHARMACOKINETICS, 1978, 3 (02) : 144 - 154
[5] STUDIES OF DRUG PROTEIN-BINDING INTERACTIONS BY FLOW-INJECTION ANALYSIS WITH FLUORIMETRIC DETECTION
ABDULLAHI, GL
MILLER, JN
STURLEY, HN
BRIDGES, JW
ANALYTICA CHIMICA ACTA, 1983, 145 (JAN) : 109 - 116
[6] PROTEIN-BINDING CHARACTERISTICS OF BUMETANIDE
WALKER, PC
BERRY, NS
EDWARDS, DJ
DEVELOPMENTAL PHARMACOLOGY AND THERAPEUTICS, 1989, 12 (01): : 13 - 18
[7] PHARMACOKINETIC CONSEQUENCES OF DRUG PROTEIN-BINDING
ROWLAND, M
ACTA PHARMACEUTICA SUECICA, 1980, 17 (02): : 83 - 83
[8] DRUG PROTEIN-BINDING IN NEWBORN INFANT
KRASNER, J
GIACOIA, GP
YAFFE, SJ
PEDIATRIC RESEARCH, 1973, 7 (04) : 317 - 317
[9] INTERACTIONS INCREASING DRUG PROTEIN-BINDING
ROMACH, MK
SELLERS, EM
KHOUW, V
NARANJO, CA
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 37 (02) : 224 - 224
[10] METHODS OF DRUG PROTEIN-BINDING DETERMINATIONS
SEBILLE, B
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1990, 4 : S151 - S161

← 1 2 3 4 5 →